Asset profile
Ropanicant
Small molecule
Evidence outlook · lead readout
NCT06836063 · Major Depressive Disorder (MDD)
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06836063: The study randomized 214 participants to two ropanicant dose groups or placebo and used quadruple masking, with change in the clinical MADRS score as the primary endpoint. Because the primary comparison and safety findings have not been reported, the study provides well-designed but currently incomplete evidence.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.